DK4034115T3 - Farmaceutisk sammensætning omfattende thrombolytisk peptid-tetrahydroisoquinolin-konjugat - Google Patents

Farmaceutisk sammensætning omfattende thrombolytisk peptid-tetrahydroisoquinolin-konjugat Download PDF

Info

Publication number
DK4034115T3
DK4034115T3 DK20868013.2T DK20868013T DK4034115T3 DK 4034115 T3 DK4034115 T3 DK 4034115T3 DK 20868013 T DK20868013 T DK 20868013T DK 4034115 T3 DK4034115 T3 DK 4034115T3
Authority
DK
Denmark
Prior art keywords
tetrahydroisoquinoline
conjugate
pharmaceutical composition
thrombolytic peptide
thrombolytic
Prior art date
Application number
DK20868013.2T
Other languages
English (en)
Inventor
David Chih-Kuang CHOU
Original Assignee
Lumosa Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumosa Therapeutics Co Ltd filed Critical Lumosa Therapeutics Co Ltd
Application granted granted Critical
Publication of DK4034115T3 publication Critical patent/DK4034115T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20868013.2T 2019-09-25 2020-09-24 Farmaceutisk sammensætning omfattende thrombolytisk peptid-tetrahydroisoquinolin-konjugat DK4034115T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905679P 2019-09-25 2019-09-25
PCT/US2020/052514 WO2021062003A1 (en) 2019-09-25 2020-09-24 Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate

Publications (1)

Publication Number Publication Date
DK4034115T3 true DK4034115T3 (da) 2025-03-24

Family

ID=74880327

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20868013.2T DK4034115T3 (da) 2019-09-25 2020-09-24 Farmaceutisk sammensætning omfattende thrombolytisk peptid-tetrahydroisoquinolin-konjugat

Country Status (24)

Country Link
US (4) US11338008B2 (da)
EP (2) EP4034115B1 (da)
JP (1) JP7649300B2 (da)
KR (1) KR102706799B1 (da)
CN (2) CN114555085B (da)
AU (1) AU2020353076B2 (da)
CA (1) CA3154762C (da)
DK (1) DK4034115T3 (da)
ES (1) ES3017234T3 (da)
FI (1) FI4034115T3 (da)
HR (1) HRP20250453T1 (da)
HU (1) HUE070923T2 (da)
IL (1) IL291380B2 (da)
LT (1) LT4034115T (da)
MX (1) MX2022003235A (da)
MY (1) MY206671A (da)
PL (1) PL4034115T3 (da)
PT (1) PT4034115T (da)
RS (1) RS66705B1 (da)
SI (1) SI4034115T1 (da)
SM (1) SMT202500115T1 (da)
TW (1) TWI838584B (da)
WO (1) WO2021062003A1 (da)
ZA (1) ZA202203140B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4034115T (lt) * 2019-09-25 2025-04-10 Lumosa Therapeutics Co., Ltd. Farmacinė kompozicija, apimanti trombolizinio peptido ir tetrahidroizochinolino konjugatą

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301200A2 (en) * 2000-05-19 2003-04-16 Bionebraska, Inc. Peptide pharmaceutical formulations
EP2385825B1 (en) * 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
US8785168B2 (en) * 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
TWI568747B (zh) 2012-09-05 2017-02-01 上海晟順生物科技有限公司 同時具溶血栓、清除自由基和血栓靶向功能的新穎化合物及其製備方法和用途
PT3006454T (pt) * 2013-06-05 2021-01-29 Shanghai Lumosa Therapeutics Co Ltd Novos compostos possuindo atividades triplas de trombólise, antitrombótica e sequestrante de radicais, e suas síntese, nanoestrutura e utilização
LT4034115T (lt) * 2019-09-25 2025-04-10 Lumosa Therapeutics Co., Ltd. Farmacinė kompozicija, apimanti trombolizinio peptido ir tetrahidroizochinolino konjugatą

Also Published As

Publication number Publication date
PL4034115T3 (pl) 2025-05-19
IL291380B1 (en) 2025-03-01
MY206671A (en) 2024-12-31
EP4034115A1 (en) 2022-08-03
CN119838019A (zh) 2025-04-18
US11707501B2 (en) 2023-07-25
CN114555085A (zh) 2022-05-27
RS66705B1 (sr) 2025-05-30
US20250186534A1 (en) 2025-06-12
TW202126634A (zh) 2021-07-16
US20240024407A1 (en) 2024-01-25
JP7649300B2 (ja) 2025-03-19
SMT202500115T1 (it) 2025-05-12
CA3154762C (en) 2024-06-11
HRP20250453T1 (hr) 2025-06-06
AU2020353076A1 (en) 2022-04-07
US20220370542A1 (en) 2022-11-24
US11338008B2 (en) 2022-05-24
IL291380B2 (en) 2025-07-01
LT4034115T (lt) 2025-04-10
KR102706799B1 (ko) 2024-09-19
CA3154762A1 (en) 2021-04-01
MX2022003235A (es) 2022-04-26
NZ786206A (en) 2024-09-27
AU2020353076B2 (en) 2024-04-18
IL291380A (en) 2022-05-01
SI4034115T1 (sl) 2025-04-30
EP4516288A2 (en) 2025-03-05
US12059448B2 (en) 2024-08-13
EP4034115A4 (en) 2023-12-06
EP4516288A3 (en) 2025-06-18
BR112022005327A2 (pt) 2022-06-14
FI4034115T3 (fi) 2025-05-05
US20210085747A1 (en) 2021-03-25
ES3017234T3 (en) 2025-05-12
WO2021062003A1 (en) 2021-04-01
TWI838584B (zh) 2024-04-11
CN114555085B (zh) 2024-12-27
HUE070923T2 (hu) 2025-07-28
ZA202203140B (en) 2023-12-20
PT4034115T (pt) 2025-03-25
JP2022549786A (ja) 2022-11-29
EP4034115B1 (en) 2025-01-29
KR20220068998A (ko) 2022-05-26

Similar Documents

Publication Publication Date Title
IL286291A (en) Compounds and conjugates thereof
DK4015003T3 (da) Forbedret antistof-oligonukleotid-konjugat
DK3655038T3 (da) Farmaceutisk sammensætning
EP3989959A4 (en) TRANSDERMAL FORMULATIONS
IL291486A (en) Therapeutic conjugates
IL285674A (en) Pharmaceutical formulations
SI3927315T1 (sl) Okusne formulacije
DK3981390T3 (da) Farmaceutisk lacosamid-sammensætning og farmaceutisk præparat deraf
EP3914234A4 (en) Pharmaceutical compositions
EP3868371A4 (en) NOVEL PHARMACEUTICAL COMPOSITION
DK3583943T3 (da) Farmaceutisk sammensætning
DK3908321T3 (da) Farmaceutisk sammensætning
EP4013441A4 (en) LARAZOTIDE FORMULATIONS
EP3705122A4 (en) DELAYED RELEASE MEDICAL COMPOSITION
SMT202400478T1 (it) Composizione farmaceutica
DK4279082T3 (da) Formuleringer
CR20220587A (es) Formulaciones farmacéuticas
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
PT3949952T (pt) Composição farmacêutica
IL291380A (en) A pharmaceutical preparation containing a peptide-tetrahydroisoquinoline conjugate of thrombus dissolution
DK3996688T3 (da) Farmaceutisk præparat
SI3827814T1 (sl) Oftalmološke formulacije
EP4032535A4 (en) PHARMACEUTICAL COMPOSITION
EP3964264A4 (en) NOVEL PHARMACEUTICAL COMPOSITION
EP4081251A4 (en) PHARMACEUTICAL COMPOSITIONS